Loading…
Loading…
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, announces that it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on November 9, 2026, and will host a conference call beginning at 8:30 a.m. Eastern time.
LifeMD (NASDAQ: LFMD - Get Free Report) and GeneDx (NASDAQ: WGS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability. Profitability This table compares LifeMD and GeneDx's net margins,
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.
T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.
LifeMD remains a Buy despite disappointing Q2 2026 results, with revenue and EBITDA guidance revised downward and a sequential subscriber decline. LFMD's core business model is profitable at an 88% gross margin, but elevated customer acquisition costs—now 59% of revenue—are pressuring EBITDA. Management is shifting strategy from auction-based marketing to partnerships with manufacturers, employers, and insurers, aiming to reduce CAC and leverage branded GLP-1 therapies.
DALLAS, Sept. 15, 2026 /PRNewswire/ -- Through an exclusive collaboration with LifeMD, eligible AT&T wireless and fiber customers receive a complimentary LifeMD membership, a $228 annual value, with on-demand access to a nationwide virtual care and pharmacy platform.
LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript
LifeMD NASDAQ: LFMD reported second-quarter revenue of $47.3 million, within its prior guidance range, while posting an adjusted EBITDA loss of approximately $3.5 million as elevated customer acquisition costs and a lower introductory price for branded GLP-1 care pressured profitability.